Table 2– Demographic and clinical characteristics of the 206 study participants
Female62 (30.1)
Age years10.4±3.7
BMI kg·m−217.2±3.1
Asthma maintenance therapy195 (94.7)
ICS# ≤250 μg·day−1143
ICS 251–500 μg·day−144
ICS >500 μg·day−11
Combination therapy ICS+LABA51
FVC % pred101.3±12.0
FEV1 % pred100.3±14.7
FeNO ppb12.5 (0–24)
Sensitised to one or more aeroallergens106 (51.5)
  • Data are presented as n (%), mean±sd, n or median (range). BMI: body mass index; ICS: inhaled corticosteroids; LABA: long-acting β-agonist; FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in 1 s; FeNO: exhaled nitric oxide fraction. #: daily dose of fluticasone (or equivalent).